Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.
Illegal immigrant sentenced to life for brutal murder of Maryland jogger
Epstein controversy fails to impact Trump's approval rating, as public interest in the case drops significantly.
Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.
Illegal immigrant sentenced to life for brutal murder of Maryland jogger
Epstein controversy fails to impact Trump's approval rating, as public interest in the case drops significantly.